Skip to Content
Merck

45706

Warfarin

PESTANAL®, analytical standard

Synonym(s):

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumafene

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H16O4
CAS Number:
81-81-2
Molecular Weight:
308.33
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329756915
EC Number:
201-377-6
Beilstein/REAXYS Number:
8868198
MDL number:
MFCD00006854

Product Name

Warfarin, PESTANAL®, analytical standard

InChI key

PJVWKTKQMONHTI-UHFFFAOYSA-N

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

SMILES string

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

grade

analytical standard

product line

PESTANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

162-164 °C (lit.)

application(s)

agriculture
environmental

format

neat

Quality Level

100

Gene Information

human ... VKORC1(79001)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Warfarin is an anticoagulant commonly used in the prevention of thrombosis and thromboembolism. Its use is studied in stroke and pulmonary fibrosis patients among many others. It is used to study potential risks and interactions with other drugs and food.

Biochem/physiol Actions

Warfarin consists of a racemic mixture of two active enantiomers, R- and S- forms. Warfarin is slower-acting than the common anticoagulant heparin. Warfarin inhibits the vitamin K-dependent synthesis of biologically active forms of the calcium-dependent clotting factors II, VII, IX and X. It inhibits regulatory factors protein C, protein S, and protein Z.

Disclaimer

Restricted to professional users. Attention − Avoid exposure − obtain special instructions before use.

signalword

Danger

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

target_organs

Blood

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM4467
BCCH4004
BCBV7416
BCBV3285

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jack Ansell et al.
Chest, 126(3 Suppl), 204S-233S (2004-09-24)
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth, Kevin J. Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine, 10.1164, 201202-03140C-201202-03140C (2012)
Daisuke Yoshioka et al.
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 17(4), 308-314 (2014-07-23)
The aim of this study was to evaluate our clinical experience with the Jarvik 2000 axial flow pump (Jarvik Heart, Inc, New York, NY, USA), a miniature axial flow left ventricular assist device (LVAD). The clinical results of eight patients
Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation.
Jeffrey I Weitz et al.
Circulation, 129(16), 1688-1694 (2014-04-23)
Ye Wang et al.
Cardiovascular drugs and therapy, 28(6), 575-585 (2014-10-17)
This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore. A Markov model was constructed to compare the lifetime costs, quality-adjusted life-years (QALYs)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service